UroGen Pharma (NASDAQ:URGN) Issues Earnings Results

UroGen Pharma (NASDAQ:URGN) posted its quarterly earnings results on Monday. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.11), Zacks reports.

UroGen Pharma Stock Performance

NASDAQ URGN opened at $9.75 on Monday. The firm has a market capitalization of $228.56 million, a P/E ratio of -3.09 and a beta of 1.12. UroGen Pharma has a fifty-two week low of $9.03 and a fifty-two week high of $20.70. The stock’s fifty day moving average is $10.45 and its two-hundred day moving average is $11.76. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on URGN. LADENBURG THALM/SH SH started coverage on shares of UroGen Pharma in a report on Wednesday, February 19th. They set a “buy” rating and a $31.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $64.00 price objective on shares of UroGen Pharma in a research report on Tuesday, February 25th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $25.00 price target on shares of UroGen Pharma in a report on Tuesday, February 18th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, UroGen Pharma presently has an average rating of “Buy” and an average target price of $40.00.

Insider Activity

In related news, General Counsel Jason Drew Smith sold 7,379 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $82,202.06. Following the sale, the general counsel now owns 26,468 shares in the company, valued at $294,853.52. This represents a 21.80 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Mark Schoenberg sold 4,551 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the transaction, the insider now directly owns 145,666 shares of the company’s stock, valued at $1,622,719.24. This represents a 3.03 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.10% of the company’s stock.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.